Sci Rep:非肌肉浸润膀胱癌的基因表达分析阐释了Tp53状态和可变剪切本的作用

2019-07-27 AlexYang MedSci原创

非肌肉浸润性膀胱癌(NMIBC)由于其具有高的复发率和频繁的跟踪调查,因此是国家医疗健康系统中的一个关键问题。最近,有研究人员在诊断为NMIBC的患者中进行了基因表达分析,从而来确定参与肿瘤起始的分子途径。研究发现,MYC和E2F在NMIBC患者中表达上调并参与了肿瘤的起始和恶化。他们的结果同样支持了可变剪切本的重要参与作用,调控了关键的途径从而有利于膀胱肿瘤的演化。由于MDM2表现出了差异化的外

非肌肉浸润性膀胱癌(NMIBC)由于其具有高的复发率和频繁的跟踪调查,因此是国家医疗健康系统中的一个关键问题。最近,有研究人员在诊断为NMIBC的患者中进行了基因表达分析,从而来确定参与肿瘤起始的分子途径。

研究发现,MYC和E2F在NMIBC患者中表达上调并参与了肿瘤的起始和恶化。他们的结果同样支持了可变剪切本的重要参与作用,调控了关键的途径从而有利于膀胱肿瘤的演化。由于MDM2表现出了差异化的外显子使用情况,研究人员在相同的患者中研究了TP53变异和蛋白表达情况。数据支持了复发是表观遗传学调节的,TP53蛋白表达量的增加有利于上述过程。另外,TP53在晚期阶段和等级的癌症中表现出了更加高频的突变,且与更差的预后相关。

最后,研究人员指出,TP53变异状态可以作为NMIBC第一阶段的潜在生物标记,从而来预测复发和预后。

原始出处:

Marta Dueñas, Andrés Pérez-Figueroa, Carla Oliveira et al. Gene Expression Analyses in Non Muscle Invasive Bladder Cancer Reveals a Role for Alternative Splicing and Tp53 Status. Sci Rep. 17 Jul 2019

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1936633, encodeId=357719366330e, content=<a href='/topic/show?id=20f5902e082' target=_blank style='color:#2F92EE;'>#表达分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90270, encryptionId=20f5902e082, topicName=表达分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=198d2500149, createdName=12498bd5m16暂无昵称, createdTime=Sun Oct 06 12:10:00 CST 2019, time=2019-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348103, encodeId=d4f51348103c4, content=<a href='/topic/show?id=d61b418860a' target=_blank style='color:#2F92EE;'>#基因表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41886, encryptionId=d61b418860a, topicName=基因表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Mon Jul 29 02:10:00 CST 2019, time=2019-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372412, encodeId=87d513e24124c, content=<a href='/topic/show?id=9d861362e53' target=_blank style='color:#2F92EE;'>#p53#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13627, encryptionId=9d861362e53, topicName=p53)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5d70341, createdName=zhishijing, createdTime=Mon Jul 29 02:10:00 CST 2019, time=2019-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458445, encodeId=6baa1458445d3, content=<a href='/topic/show?id=50a81e6869e' target=_blank style='color:#2F92EE;'>#TP53#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17686, encryptionId=50a81e6869e, topicName=TP53)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d276073420, createdName=zblhy, createdTime=Mon Jul 29 02:10:00 CST 2019, time=2019-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039941, encodeId=6a1c103994115, content=膀胱癌真怪,明明是免疫敏感性肿瘤,为什么PD-1治疗效果不好呢?难道靶点不对?将来CD47会不会有效, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Sat Jul 27 14:10:00 CST 2019, time=2019-07-27, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1936633, encodeId=357719366330e, content=<a href='/topic/show?id=20f5902e082' target=_blank style='color:#2F92EE;'>#表达分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90270, encryptionId=20f5902e082, topicName=表达分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=198d2500149, createdName=12498bd5m16暂无昵称, createdTime=Sun Oct 06 12:10:00 CST 2019, time=2019-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348103, encodeId=d4f51348103c4, content=<a href='/topic/show?id=d61b418860a' target=_blank style='color:#2F92EE;'>#基因表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41886, encryptionId=d61b418860a, topicName=基因表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Mon Jul 29 02:10:00 CST 2019, time=2019-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372412, encodeId=87d513e24124c, content=<a href='/topic/show?id=9d861362e53' target=_blank style='color:#2F92EE;'>#p53#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13627, encryptionId=9d861362e53, topicName=p53)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5d70341, createdName=zhishijing, createdTime=Mon Jul 29 02:10:00 CST 2019, time=2019-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458445, encodeId=6baa1458445d3, content=<a href='/topic/show?id=50a81e6869e' target=_blank style='color:#2F92EE;'>#TP53#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17686, encryptionId=50a81e6869e, topicName=TP53)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d276073420, createdName=zblhy, createdTime=Mon Jul 29 02:10:00 CST 2019, time=2019-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039941, encodeId=6a1c103994115, content=膀胱癌真怪,明明是免疫敏感性肿瘤,为什么PD-1治疗效果不好呢?难道靶点不对?将来CD47会不会有效, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Sat Jul 27 14:10:00 CST 2019, time=2019-07-27, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1936633, encodeId=357719366330e, content=<a href='/topic/show?id=20f5902e082' target=_blank style='color:#2F92EE;'>#表达分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90270, encryptionId=20f5902e082, topicName=表达分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=198d2500149, createdName=12498bd5m16暂无昵称, createdTime=Sun Oct 06 12:10:00 CST 2019, time=2019-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348103, encodeId=d4f51348103c4, content=<a href='/topic/show?id=d61b418860a' target=_blank style='color:#2F92EE;'>#基因表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41886, encryptionId=d61b418860a, topicName=基因表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Mon Jul 29 02:10:00 CST 2019, time=2019-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372412, encodeId=87d513e24124c, content=<a href='/topic/show?id=9d861362e53' target=_blank style='color:#2F92EE;'>#p53#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13627, encryptionId=9d861362e53, topicName=p53)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5d70341, createdName=zhishijing, createdTime=Mon Jul 29 02:10:00 CST 2019, time=2019-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458445, encodeId=6baa1458445d3, content=<a href='/topic/show?id=50a81e6869e' target=_blank style='color:#2F92EE;'>#TP53#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17686, encryptionId=50a81e6869e, topicName=TP53)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d276073420, createdName=zblhy, createdTime=Mon Jul 29 02:10:00 CST 2019, time=2019-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039941, encodeId=6a1c103994115, content=膀胱癌真怪,明明是免疫敏感性肿瘤,为什么PD-1治疗效果不好呢?难道靶点不对?将来CD47会不会有效, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Sat Jul 27 14:10:00 CST 2019, time=2019-07-27, status=1, ipAttribution=)]
    2019-07-29 zhishijing
  4. [GetPortalCommentsPageByObjectIdResponse(id=1936633, encodeId=357719366330e, content=<a href='/topic/show?id=20f5902e082' target=_blank style='color:#2F92EE;'>#表达分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90270, encryptionId=20f5902e082, topicName=表达分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=198d2500149, createdName=12498bd5m16暂无昵称, createdTime=Sun Oct 06 12:10:00 CST 2019, time=2019-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348103, encodeId=d4f51348103c4, content=<a href='/topic/show?id=d61b418860a' target=_blank style='color:#2F92EE;'>#基因表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41886, encryptionId=d61b418860a, topicName=基因表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Mon Jul 29 02:10:00 CST 2019, time=2019-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372412, encodeId=87d513e24124c, content=<a href='/topic/show?id=9d861362e53' target=_blank style='color:#2F92EE;'>#p53#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13627, encryptionId=9d861362e53, topicName=p53)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5d70341, createdName=zhishijing, createdTime=Mon Jul 29 02:10:00 CST 2019, time=2019-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458445, encodeId=6baa1458445d3, content=<a href='/topic/show?id=50a81e6869e' target=_blank style='color:#2F92EE;'>#TP53#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17686, encryptionId=50a81e6869e, topicName=TP53)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d276073420, createdName=zblhy, createdTime=Mon Jul 29 02:10:00 CST 2019, time=2019-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039941, encodeId=6a1c103994115, content=膀胱癌真怪,明明是免疫敏感性肿瘤,为什么PD-1治疗效果不好呢?难道靶点不对?将来CD47会不会有效, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Sat Jul 27 14:10:00 CST 2019, time=2019-07-27, status=1, ipAttribution=)]
    2019-07-29 zblhy
  5. [GetPortalCommentsPageByObjectIdResponse(id=1936633, encodeId=357719366330e, content=<a href='/topic/show?id=20f5902e082' target=_blank style='color:#2F92EE;'>#表达分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90270, encryptionId=20f5902e082, topicName=表达分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=198d2500149, createdName=12498bd5m16暂无昵称, createdTime=Sun Oct 06 12:10:00 CST 2019, time=2019-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348103, encodeId=d4f51348103c4, content=<a href='/topic/show?id=d61b418860a' target=_blank style='color:#2F92EE;'>#基因表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41886, encryptionId=d61b418860a, topicName=基因表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Mon Jul 29 02:10:00 CST 2019, time=2019-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372412, encodeId=87d513e24124c, content=<a href='/topic/show?id=9d861362e53' target=_blank style='color:#2F92EE;'>#p53#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13627, encryptionId=9d861362e53, topicName=p53)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5d70341, createdName=zhishijing, createdTime=Mon Jul 29 02:10:00 CST 2019, time=2019-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458445, encodeId=6baa1458445d3, content=<a href='/topic/show?id=50a81e6869e' target=_blank style='color:#2F92EE;'>#TP53#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17686, encryptionId=50a81e6869e, topicName=TP53)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d276073420, createdName=zblhy, createdTime=Mon Jul 29 02:10:00 CST 2019, time=2019-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039941, encodeId=6a1c103994115, content=膀胱癌真怪,明明是免疫敏感性肿瘤,为什么PD-1治疗效果不好呢?难道靶点不对?将来CD47会不会有效, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Sat Jul 27 14:10:00 CST 2019, time=2019-07-27, status=1, ipAttribution=)]
    2019-07-27 留走人康

    膀胱癌真怪,明明是免疫敏感性肿瘤,为什么PD-1治疗效果不好呢?难道靶点不对?将来CD47会不会有效

    0

相关资讯

NCCN临床实践指南:膀胱癌(2019.V4)

2019年7月,美国国家综合癌症网络(NCCN)发布了膀胱癌指南2019年第4版,指南主要内容包括: 指南更新摘要 膀胱癌 临床表现和初始评估 非侵袭性或Tis,初步评估/手术治疗 肌层侵袭或转移,初步评估/手术治疗,额外检查 膀胱/移行细胞癌影像学检查 手术治疗原则 病理检查原则 非肌层浸润性膀胱癌复发概率 膀胱癌:非肌层以及移行细胞变异组织学 术后随访 膀胱灌注治疗原则 化疗原则 侵袭性疾病放

Nat Med:G9a/DNMT的抑制能够激发免疫调控的膀胱癌退化

膀胱癌在晚期、肌层浸润阶段是致死的,并且治疗的方法非常有限。最近的分子特性鉴定确定了膀胱癌新的(表观)遗传驱使因子和潜在的靶位点。免疫检查点抑制剂具有很明显的疗效,但是仅仅适用于一部分的膀胱癌患者。最近,有研究人员表明了G9a (EHMT2)的表达与膀胱癌不良临床结果相关,并且利用一种新的抑制剂(CM-272)靶定G9a/DNMT甲基转移酶活性能够诱导细胞凋亡和免疫原性细胞死亡。研究人员在4个基因

Neon新疫苗“一箭三雕”连破肺癌、膀胱癌、黑色素瘤

“救命神器”天上来!默沙东无人机完成零下70摄氏度低温药品递送Direct Relief组织宣布,由默沙东(MSD)、AT&T、Softbox和Direct Relief联合进行,使用无人机向偏远地区递送需要低温保存的药品和疫苗的概念验证研究获得成功。这一结果可能代表着生物医药物流创新和人道主义活动方面的重要进步。图片来源:默沙东提供对于地处偏远区域或者发生自然灾害地区的人们来说,由于

BJU Int:神经保留和前列腺囊保留膀胱切除术的长期功能和肿瘤结果研究

最近,有研究人员评估了神经保留膀胱前列腺切除术(NSCP)和前列腺囊保留膀胱切除术(PCSC)在治疗器官局限性膀胱癌中的技术可行性、肿瘤和功能结果。研究时间为2001年4月到2012年6月,共有60名患者经历了PCSC,47名患者进行了NSCP治疗。研究发现,PCSC和NSCP患者组中的平均跟踪调查时间分别为73个月和62个月,5年CSS在PCSC组中为90%,在NSCP组中为78%(P=0.05

肌层浸润性膀胱癌的根治性切除与保留膀胱综合治疗

膀胱癌是起源于膀胱尿路上皮的恶性肿瘤,是泌尿系统最常见的恶性肿瘤之一,肌层浸润性尿路上皮癌恶性程度相对更高。目前临床上根治性膀胱切除术同时行盆腔淋巴结清扫术,是肌层浸润性膀胱癌的标准治疗方案,然而因为手术和术后的并发症等,给患者的生活质量带来严重影响,随着患者对于生活质量要求的提高,部分患者开始选择保留膀胱治疗。特邀浙江大学医学院附属第一医院的金百冶教授,就肌层浸润性膀胱癌的临床治疗策略选择进行专

Clin Chem:无创检测膀胱癌

目前膀胱癌的诊断和监测依赖膀胱镜检查,这是一种侵入性和昂贵的手术。以往基于尿液检测膀胱癌的研究主要集中在基于表达特定异常的肿瘤的靶向方法上。本研究的目的是通过全基因组甲基化和拷贝数畸变(CNAs)的评估来非侵入性检测膀胱癌。此外,还研究了游离(cf)DNA片段的大小。 研究人员对46例膀胱癌患者和39例无癌血尿对照者进行尿cfDNA的浅深度双端全基因组测序。通过甲基化反褶积、(b)全局低甲基